Evonik Launches New Technology to Improve Solubility of Oral Small Molecules
Evonik recently announced it now offers EUDRATEC SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products. This emulsion-based process technology overcomes solubility hurdles that cannot be resolved by existing manufacturing technologies. As more than 70% of new small molecules are insoluble, EUDRATEC SoluFlow therefore enables the development of new oral therapeutics in diverse areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes.
“Our new technology opens doors to a wider spectrum of oral drugs by enabling the use of molecules that were previously considered insoluble. We look forward to working with customers to develop oral drugs for better, healthier lives,” said Paul Spencer, Head of the Product line Drug Delivery & Medical Device Solutions at Evonik’s Health Care business.
EUDRATEC SoluFlow is a technology and service that turns a poorly soluble drug into a free-flowing powder of the amorphous solid dispersion (ASD). This ASD can easily be compressed into tablets or filled into capsules, reducing the number and complexity of post-processing steps. The unique emulsion-based process uses standard pharma equipment to manufacture uniform microparticles that have a controlled target size and are produced at high yield. Case studies indicate that the solubility enhancement achieved through EUDRATEC SoluFlow also translates into an improved pharmacokinetic performance of the drugs.
“With this latest innovation to our EUDRATEC portfolio, we are delighted to help with tough solubility problems and fulfill an unmet need for our pharma partners and their patients,” said Jessica Mueller-Albers, strategic marketing director of the global business segment Oral Drug Delivery Solutions at Evonik’s Health Care business.
EUDRATEC is Evonik’s platform of oral drug delivery technologies for targeted release. This highly innovative solutions portfolio is being continuously expanded in response to the needs of the pharmaceutical industry. In 2020, Evonik launched EUDRATEC Fasteric for enteric protection and rapid release in the upper small intestine.
Evonik Health Care is one of the world’s leading CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest contract manufacturers of active pharmaceutical ingredients (APIs) that require complex chemistry and multiple-step syntheses.
Total Page Views: 1089
